Topics:

Rheumatoid Arthritis

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Rheumatoid Arthritis

(AAOS2015) Patients with inflammatory arthritis appear to be at less risk for complications from knee or hip replacement than those with osteoarthritis, a large national database reveals. But those with ankylosing spondylitis have greater risk.

The increased risk for venous thromoboembolism after surgery among patients with rheumatic disease appears to trace to those conditions with a clotting component. However, joint surgery in general has a high risk of this complication.

The UK government's health assessment agency has found that combinations of traditional drugs offer results for rheumatoid arthritis not inferior to those of tumor necrosis factor inhibitors, although the latter work more quickly.

vaccine

Tofacitinib affects response to the pneumonia (but not the influenza) vaccine in rheumatoid arthritis patients, especially those also taking methotrexate,

periodontal disease

Reviews by a rheumatologist and an oral health specialist spell out the evidence that links periodontal disease and rheumatoid arthritis. Can effective treatment of teeth and gums alter the course of the rheumatic disease?

The American College of Rheumatology has issued a public statement of concern about the need for policy changes, studies, and post-marketing vigilance in the wake of FDA's approval of the first US biosimilar.

Pages

Subscribe to Rheumatoid Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.